ArticleThe Journal of investigative dermatology2020
Improved Cutaneous Genetic Immunization by Microneedle Array Delivery of an Adjuvanted Adenovirus Vaccine.
Abstract readLetter
In one paragraph
Article in The Journal of investigative dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dissolving microneedles for nucleic acid delivery: A systematic search, review, and data synthesis.Acta biomaterialia · 2025Pooled it
- Immunogenicity of a bivalent recombinant adenovirus expressing VP1 proteins of bovine norovirus and bovine nebovirus in mice and calves.BMC microbiology · 2025Article
- Development and Evaluation of Dual Microneedle Array Patch for Sequential Intradermal Delivery of Adjuvant and Antigen.Pharmaceutical research · 2025Article
- Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic.Molecular biotechnology · 2024Review
- A microarray patch SARS-CoV-2 vaccine induces sustained antibody responses and polyfunctional cellular immunity.iScience · 2022Article
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- Microneedle-mediated drug delivery for cutaneous diseases.Frontiers in bioengineering and biotechnology · 2022Review
- Vaccine delivery systems toward lymph nodes.Advanced drug delivery reviews · 2021Review
- Research Techniques Made Simple: Skin-Targeted Drug and Vaccine Delivery Using Dissolvable Microneedle Arrays.The Journal of investigative dermatology · 2021Article
- Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs.Acta pharmaceutica Sinica. B · 2021Review
- A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.European journal of immunology · 2021Article
- Microarray patches enable the development of skin-targeted vaccines against COVID-19.Advanced drug delivery reviews · 2021Review
- Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks.Vaccines · 2021Article
- Development of vaccine formulations: past, present, and future.Drug delivery and translational research · 2021Review
- Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.Expert opinion on drug delivery · 2021Review
- Engineering Antiviral Vaccines.ACS nano · 2020Review
- Advances in skin science enable the development of a COVID-19 vaccine.Journal of the American Academy of Dermatology · 2020Article
- Review
- Application of microneedle patches for drug delivery; doorstep to novel therapies.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Geza ErdosDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Stephen C BalmertDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Cara Donahue CareyDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Gabriel D FaloDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Nikita A PatelDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Jiying ZhangDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Andrea GambottoDepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Emrullah KorkmazDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Bioengineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh, Pennsylvania, USA.
Louis D FaloDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Bioengineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh, Pennsylvania, USA; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; The UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA; The McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Electronic address: lof2@pitt.edu.
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MEngineering the Skin Microenvironment to Promote Allergen ToleranceR01AR074285 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D, LITTLE, STEVEN R · 2018 to 2023
$3.0MMNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic DermatitisR01AR071277 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D, LARREGINA, ADRIANA T · 2017 to 2021
$2.4MManipulating Cutaneous Neuroimmunity to Treat Contact DermatitisR01AR068249 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D, LARREGINA, ADRIANA T · 2015 to 2019
$2.1MTraining Program in Skin Biology and CancerT32CA175294 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2014 to 2018
$973kPre-clinical evaluation of a Zika virus vaccineR21AI130180 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GAMBOTTO, ANDREA · 2017 to 2018
$426kNCI NIH HHS P30 CA047904NCI NIH HHS T32 CA175294NIAID NIH HHS R21 AI130180NIAID NIH HHS UM1 AI106701NIAMS NIH HHS R01 AR068249NIAMS NIH HHS R01 AR071277NIAMS NIH HHS R01 AR074285
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenoviridaeAdjuvants, ImmunologicAdministration, CutaneousAnimalsDrug Delivery SystemsGenetic VectorsImmunogenicity, VaccineMiceOvalbuminPoly I-CToll-Like Receptor 3Vaccines, DNAAdjuvants, ImmunologicOvalbuminPoly I-CTLR3 protein, humanToll-Like Receptor 3Vaccines, DNAMNA, microneedle arrayOVA, ovalbuminPoly(I:C), polyinosinic acid:polycytidylic acidTLR, toll-like receptor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.